Omeros Corporation (OMER) is a Healthcare stock trading at $10.23 (as of 2026-06-18), with a market capitalization of $799.02M and a trailing P/E of 9.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Omeros Corporation is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes small-molecule and protein therapeutics. Its programs address inflammation, complement-mediated diseases, immune-system-related cancers, and addictive and compulsive disorders, including clinical-stage candidates such as narsoplimab and OMS405.